Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080880 |
| Name | diffuse glioma, H3 G34 mutant |
| Definition | A histone mutated tumor that has_material_basis_in mutations in codon 34 of the H3 histone family 3A protein. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse glioma, H3 G34 mutant |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Completed | USA | 0 |
| NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Terminated | USA | ITA | GBR | DEU | 0 |
| NCT05457959 | Phase I | Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | Withdrawn | USA | 0 |
| NCT05843253 | Phase II | Ribociclib + Temozolomide Everolimus + Ribociclib | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Recruiting | USA | NLD | GBR | DEU | CAN | AUS | 0 |
| NCT06342908 | Phase I | Neoantigen-targeted ppDC Poly ICLC | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | Recruiting | USA | 0 |
| NCT06413706 | Phase II | Abemaciclib + Temozolomide Temozolomide | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Recruiting | USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS | 1 |
| NCT06630260 | Phase Ib/II | Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) | Recruiting | GBR | 0 |
| NCT06632236 | Phase I | Amivantamab-vmjw | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) | Recruiting | GBR | 0 |
| NCT06894979 | Phase I | AZD1390 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |
| NCT06896110 | Phase I | Azacitidine + Nivolumab | Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma | Enrolling by invitation | USA | 0 |
| NCT06914479 | Phase I | AdV-Flt3L + AdV-HSV1-TK + Valganciclovir | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | Not yet recruiting | USA | 0 |
| NCT07223034 | Phase I | lutetium Lu 177 vipivotide tetraxetan + Temozolomide | A Study of 177Lu-PSMA-617 in People With Gliomas | Recruiting | USA | 0 |